Gland Pharma Limited — Q2 FY24
Gland Pharma reported consolidated revenue of INR 1,373.4 crore in Q2 FY24, up 32% YoY, driven by Cenexi acquisition and US market recovery.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY24
U.S. sequential growth expected
Management expects steady sequential growth in U.S. revenue, with no decline anticipated.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY24
Cenexi margin improvement in 1-2 quarters
Cenexi EBITDA margins are expected to improve in the next 1-2 quarters through operational efficiencies.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY24
Enoxaparin run rate to normalize from Q2
Enoxaparin sales are expected to pick up from next quarter as inventory rationalization ends.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1